Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer

View ORCID ProfileJorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E. Buendia-Buendia, Alyssa Pereslete, Daniel L. Abravanel, Arlindo R. Ferreira, Eileen Wrabel, Karla Helvie, Melissa E. Hughes, Ann H. Partridge, Beth Overmoyer, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney, Nikhil Wagle
doi: https://doi.org/10.1101/2022.07.11.22277416
Jorge Gómez Tejeda Zañudo
1Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorge Gómez Tejeda Zañudo
Romualdo Barroso-Sousa
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
4Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esha Jain
1Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingchun Jin
5Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianyu Li
5Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge E. Buendia-Buendia
1Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alyssa Pereslete
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel L. Abravanel
1Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arlindo R. Ferreira
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eileen Wrabel
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karla Helvie
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa E. Hughes
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann H. Partridge
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beth Overmoyer
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy U. Lin
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nabihah Tayob
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
5Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara M. Tolaney
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Sara_Tolaney@dfci.harvard.edu Nikhil_Wagle@dfci.harvard.edu
Nikhil Wagle
1Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Sara_Tolaney@dfci.harvard.edu Nikhil_Wagle@dfci.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Data Availability

Tumor and germline whole-exome sequencing data and RNA sequencing data generated and analyzed for this study are in the process of being deposited in dbGaP and will be available upon publication of the manuscript. Additional data generated in this study including clinical trial data, patient metadata, and tumor exome analysis are available in the Supplementary Data.

Back to top
PreviousNext
Posted July 12, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E. Buendia-Buendia, Alyssa Pereslete, Daniel L. Abravanel, Arlindo R. Ferreira, Eileen Wrabel, Karla Helvie, Melissa E. Hughes, Ann H. Partridge, Beth Overmoyer, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney, Nikhil Wagle
medRxiv 2022.07.11.22277416; doi: https://doi.org/10.1101/2022.07.11.22277416
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E. Buendia-Buendia, Alyssa Pereslete, Daniel L. Abravanel, Arlindo R. Ferreira, Eileen Wrabel, Karla Helvie, Melissa E. Hughes, Ann H. Partridge, Beth Overmoyer, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney, Nikhil Wagle
medRxiv 2022.07.11.22277416; doi: https://doi.org/10.1101/2022.07.11.22277416

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1101)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9782)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2318)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11656)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2148)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2188)
  • Public and Global Health (4673)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)